Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-16
DOI
10.1002/ejhf.1536
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
- (2018) Milton Packer et al. Lancet Diabetes & Endocrinology
- Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study
- (2018) Desiree Abdurrachim et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence
- (2017) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Ca2+/calmodulin-dependent protein kinase II contributes to intracellular pH recovery from acidosis via Na+/H+ exchanger activation
- (2009) Martín Vila-Petroff et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Chronic inhibition of the Na+/H+- exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling
- (2008) A Baartscheer et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now